论文部分内容阅读
目前转移性肾细胞癌(mRCC)是最难治的恶性肿瘤之一。基于肾细胞癌(RCC)发生分子机制的阐明,导致了发展有希望治疗靶点的新药。在临床研究中,舒尼替尼和索拉芬尼是治疗晚期(A)或mRCC是具有明显效果和可处理毒性的药物,属于口服的多靶点酪氨酸激酶抑制剂,抑制血管内皮生长因子受体(VEGFR)、血小板衍生的生长因子受体(PDGFR)和C-KIT受体酪氨酸激酶,很快被批准作为治疗RCC的第二线药物,并将用作第一线治疗。舒尼替尼或索拉芬尼作为单剂治疗与联合方案治疗RCC值得进一步研究。
At present, metastatic renal cell carcinoma (mRCC) is one of the most refractory malignancies. The elucidation of the molecular mechanisms underlying renal cell carcinoma (RCC) led to the development of new drugs with promising therapeutic targets. In clinical studies, sunitinib and sorafenib are late-stage treatment (A) or mRCC is a drug with significant effect and ability to handle toxicity, belongs to the oral multi-target tyrosine kinase inhibitor and inhibits vascular endothelial growth Factor Receptor (VEGFR), Platelet Derived Growth Factor Receptor (PDGFR) and C-KIT Receptor Tyrosine Kinase, were soon approved as second-line drugs for the treatment of RCC and will be used as first-line therapy. Sunitinib or sorafenib as a single agent and combined regimens for the treatment of RCC deserve further study.